Jazz Pharmaceuticals plc (NASDAQ:JAZZ) is Thompson Siegel & Walmsley LLC’s 9th Largest Position

Thompson Siegel & Walmsley LLC decreased its stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 10.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 700,922 shares of the specialty pharmaceutical company’s stock after selling 80,293 shares during the period. Jazz Pharmaceuticals makes up 1.3% of Thompson Siegel & Walmsley LLC’s portfolio, making the stock its 9th biggest position. Thompson Siegel & Walmsley LLC owned 1.16% of Jazz Pharmaceuticals worth $86,319,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also recently bought and sold shares of JAZZ. Pacer Advisors Inc. raised its stake in Jazz Pharmaceuticals by 15.3% during the third quarter. Pacer Advisors Inc. now owns 2,099,378 shares of the specialty pharmaceutical company’s stock valued at $233,892,000 after buying an additional 278,465 shares in the last quarter. Cinctive Capital Management LP acquired a new stake in Jazz Pharmaceuticals during the third quarter valued at approximately $14,277,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in Jazz Pharmaceuticals by 135.3% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 174,078 shares of the specialty pharmaceutical company’s stock valued at $19,394,000 after buying an additional 100,112 shares in the last quarter. GW&K Investment Management LLC raised its position in shares of Jazz Pharmaceuticals by 26.6% during the 4th quarter. GW&K Investment Management LLC now owns 464,003 shares of the specialty pharmaceutical company’s stock worth $57,142,000 after purchasing an additional 97,589 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. raised its position in shares of Jazz Pharmaceuticals by 501.4% during the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 112,055 shares of the specialty pharmaceutical company’s stock worth $13,800,000 after purchasing an additional 93,422 shares during the period. Hedge funds and other institutional investors own 89.14% of the company’s stock.

Insider Activity

In other news, CEO Bruce C. Cozadd sold 1,500 shares of the firm’s stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $122.31, for a total value of $183,465.00. Following the sale, the chief executive officer now directly owns 439,744 shares of the company’s stock, valued at approximately $53,785,088.64. This trade represents a 0.34 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Neena M. Patil sold 3,800 shares of the firm’s stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $144.87, for a total value of $550,506.00. Following the completion of the sale, the executive vice president now directly owns 33,318 shares in the company, valued at approximately $4,826,778.66. This represents a 10.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 28,736 shares of company stock valued at $4,022,825. 4.20% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the company. Cantor Fitzgerald cut Jazz Pharmaceuticals from an “overweight” rating to a “neutral” rating and increased their price target for the stock from $140.00 to $150.00 in a research report on Wednesday, February 26th. UBS Group upgraded Jazz Pharmaceuticals from a “neutral” rating to a “buy” rating and raised their target price for the company from $145.00 to $179.00 in a research report on Friday, March 7th. JPMorgan Chase & Co. raised their target price on Jazz Pharmaceuticals from $200.00 to $209.00 and gave the company an “overweight” rating in a research report on Wednesday, February 26th. Royal Bank of Canada lowered their target price on Jazz Pharmaceuticals from $179.00 to $178.00 and set an “outperform” rating on the stock in a research report on Wednesday, February 26th. Finally, Truist Financial raised their target price on Jazz Pharmaceuticals from $220.00 to $230.00 and gave the company a “buy” rating in a research report on Thursday, March 6th. One analyst has rated the stock with a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $190.53.

Jazz Pharmaceuticals Trading Down 2.0 %

Shares of NASDAQ:JAZZ opened at $134.16 on Thursday. The company has a market cap of $8.15 billion, a P/E ratio of 18.90, a P/E/G ratio of 1.04 and a beta of 0.44. The stock’s 50-day moving average is $128.92 and its 200-day moving average is $120.49. Jazz Pharmaceuticals plc has a 52-week low of $99.06 and a 52-week high of $148.06. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.